Cargando…

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy in human breast cancer is still a matter of investigation. 157 patients with T2-4, N0-1, M0 breast cancer received primary chemotherapy consisting of either the CMF regimen + tamoxifen (the fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bottini, A, Berruti, A, Bersiga, A, Brizzi, M P, Bruzzi, P, Aguggini, S, Brunelli, A, Bolsi, G, Allevi, G, Generali, D, Betri, E, Bertoli, G, Alquati, P, Dogliotti, L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375158/ https://www.ncbi.nlm.nih.gov/pubmed/11710821 http://dx.doi.org/10.1054/bjoc.2001.2048

Ejemplares similares

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2003)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
por: Fox, Stephen B, et al.
Publicado: (2011)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

Lung carcinoid tumours: histology and Ki‐67, the eternal rivalry
por: Centonze, Giovanni, et al.
Publicado: (2022)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
por: Jaros, E., et al.
Publicado: (1992)

Evaluation of Ki-67 expression in feline non-ocular melanocytic tumours
por: Sabattini, Silvia, et al.
Publicado: (2018)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Prognostic impact of Ki‐67 proliferative index in resectable pancreatic ductal adenocarcinoma
por: Pergolini, I., et al.
Publicado: (2019)

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma
por: Song, Jinbo, et al.
Publicado: (2021)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
por: Berruti, A, et al.
Publicado: (1999)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images
por: Joseph, Jesuchristopher, et al.
Publicado: (2019)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The Ki67 index a prognostic marker in medullary thyroid carcinoma
por: Tisell, L E, et al.
Publicado: (2003)

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
por: Lindsay, C. R., et al.
Publicado: (2016)

Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67.
por: Brown, D. C., et al.
Publicado: (1988)

Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast
por: Ali, Nurul Atiah Mohd, et al.
Publicado: (2020)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Association of Ki-67 With Clinicopathological Factors in Breast Cancer
por: ., Nishit, et al.
Publicado: (2021)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

The value of the FDG-GaTate and proliferation marker (ki-67) in the assessment of neuroendocrine tumours (NETs)
por: Fikri, AS Fathinul, et al.
Publicado: (2015)

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation
por: Cidado, Justin, et al.
Publicado: (2016)

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
por: Davey, Matthew G., et al.
Publicado: (2021)

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
por: Lazzeroni, M, et al.
Publicado: (2013)

Immunolocalization of Ki-67 in different periodontal conditions
por: Preethi, Penubolu Lakshmi, et al.
Publicado: (2014)

Clinicopathological Profile of Primary Hyperparathyroidism with Special Reference to Ki-67 Labelling Index
por: Thanveer, Azhar S., et al.
Publicado: (2023)

Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification
por: Nielsen, Ljudmilla A. G., et al.
Publicado: (2018)

Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index
por: Lea, Dordi, et al.
Publicado: (2021)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling
por: Barricelli, Barbara Rita, et al.
Publicado: (2019)

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Boyaci, Ceren, et al.
Publicado: (2021)

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
por: Selmani, Zohair, et al.
Publicado: (2022)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Dynamic chromosomal interactions and control of heterochromatin positioning by Ki‐67
por: van Schaik, Tom, et al.
Publicado: (2022)

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort
por: Fisher, G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sjmsurip23pdjserhjimtj44s5